These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19679832)

  • 1. Dysfunctional HDL as a diagnostic and therapeutic target.
    Smith JD
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):151-5. PubMed ID: 19679832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis.
    Wong NC
    Curr Opin Investig Drugs; 2007 Sep; 8(9):718-28. PubMed ID: 17729183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of dysfunctional high-density lipoprotein by myeloperoxidase.
    Nicholls SJ; Zheng L; Hazen SL
    Trends Cardiovasc Med; 2005 Aug; 15(6):212-9. PubMed ID: 16182131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein.
    Smith JD
    J Clin Lipidol; 2010; 4(5):382-8. PubMed ID: 21076633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase-mediated loss of function.
    Peng DQ; Brubaker G; Wu Z; Zheng L; Willard B; Kinter M; Hazen SL; Smith JD
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2063-70. PubMed ID: 18688016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloperoxidase and inflammatory proteins: pathways for generating dysfunctional high-density lipoprotein in humans.
    Vaisar T; Shao B; Green PS; Oda MN; Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Nov; 9(5):417-24. PubMed ID: 18001626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein carbamylation renders high-density lipoprotein dysfunctional.
    Holzer M; Gauster M; Pfeifer T; Wadsack C; Fauler G; Stiegler P; Koefeler H; Beubler E; Schuligoi R; Heinemann A; Marsche G
    Antioxid Redox Signal; 2011 Jun; 14(12):2337-46. PubMed ID: 21235354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein.
    Shao B; Oda MN; Oram JF; Heinecke JW
    Curr Opin Cardiol; 2006 Jul; 21(4):322-8. PubMed ID: 16755201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2H2O-based high-density lipoprotein turnover method for the assessment of dynamic high-density lipoprotein function in mice.
    Kasumov T; Willard B; Li L; Li M; Conger H; Buffa JA; Previs S; McCullough A; Hazen SL; Smith JD
    Arterioscler Thromb Vasc Biol; 2013 Aug; 33(8):1994-2003. PubMed ID: 23766259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.
    Castellani LW; Navab M; Van Lenten BJ; Hedrick CC; Hama SY; Goto AM; Fogelman AM; Lusis AJ
    J Clin Invest; 1997 Jul; 100(2):464-74. PubMed ID: 9218525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfunctional high-density lipoprotein.
    Feng H; Li XA
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):156-62. PubMed ID: 19306527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and function of HDL mimetics.
    Navab M; Shechter I; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):164-8. PubMed ID: 19608977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle.
    Undurti A; Huang Y; Lupica JA; Smith JD; DiDonato JA; Hazen SL
    J Biol Chem; 2009 Nov; 284(45):30825-35. PubMed ID: 19726691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
    Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST
    Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney as modulator and target of "good/bad" HDL.
    Zhong J; Yang H; Kon V
    Pediatr Nephrol; 2019 Oct; 34(10):1683-1695. PubMed ID: 30291429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection.
    Meyers CD; Kashyap ML
    Curr Opin Cardiol; 2004 Jul; 19(4):366-73. PubMed ID: 15218398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The paradox of dysfunctional high-density lipoprotein.
    Ansell BJ; Fonarow GC; Fogelman AM
    Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy.
    Linton MF; Yancey PG; Tao H; Davies SS
    Circ Res; 2023 May; 132(11):1521-1545. PubMed ID: 37228232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional HDL and atherosclerotic cardiovascular disease.
    Rosenson RS; Brewer HB; Ansell BJ; Barter P; Chapman MJ; Heinecke JW; Kontush A; Tall AR; Webb NR
    Nat Rev Cardiol; 2016 Jan; 13(1):48-60. PubMed ID: 26323267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiinflammatory actions of HDL: a new insight.
    Rye KA; Barter PJ
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1890-1. PubMed ID: 18946054
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.